# Predicting the Unpredictable: AI-Driven Prognosis in Pancreatic Neuroendocrine Neoplasms

## TL;DR

This paper reviews how AI can help predict outcomes for pancreatic neuroendocrine tumors but highlights challenges in validation and ethics.

## Contribution

The paper provides a critical review of AI-based tools for predicting clinical outcomes in Pan-NENs and identifies barriers to clinical adoption.

## Key findings

- AI tools can integrate multimodal data to improve survival predictions for Pan-NEN patients.
- Limited retrospective data and lack of external validation hinder AI adoption in clinical practice.
- Ethical and transparency concerns remain unresolved in AI-driven prognostic models.

## Abstract

Pancreatic Neuroendocrine Neoplasms (Pan-NENs) represent a unique challenge in oncology due to their varied nature, making accurate risk stratification and treatment selection challenging. Artificial Intelligence (AI) has emerged as a powerful tool capable of mining extensive clinical and diagnostic data to refine predictions regarding patient survival and metastatic spread. Despite enthusiastic early results, the field faces hurdles, including ethical dilemmas and a lack of large-scale, validated studies. This review investigates the current landscape of AI-based predictive tools and their effectiveness in forecasting clinical outcomes for Pan-NEN patients.

The clinical management of Pancreatic Neuroendocrine Neoplasms (Pan-NENs) is complicated by the disease’s intrinsic variability, which creates significant hurdles for accurate risk profiling and the standardization of treatment protocols. Recently, Artificial Intelligence (AI) has offered a promising avenue to address these challenges. By integrating and processing high-dimensional multimodal datasets (encompassing clinical history, radiomics, and pathology), these computational tools can refine survival forecasts and support the development of personalized medicine. However, the transition from experimental success to routine clinical use is currently obstructed by reliance on limited, retrospective cohorts that lack external validation, alongside unresolved concerns regarding algorithmic transparency and ethical governance. This review evaluates the current landscape of AI-driven prognostic modeling for Pan-NENs and critically examines the pathway towards their reliable integration into clinical practice.